757 related articles for article (PubMed ID: 17928874)
21. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.
Valdespino V; Gorodezky C; Ortiz V; Kaufmann AM; Roman-Basaure E; Vazquez A; Berumen J
Gynecol Oncol; 2005 Jan; 96(1):92-102. PubMed ID: 15589586
[TBL] [Abstract][Full Text] [Related]
22. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector.
Liu Y; Chiriva-Internati M; Grizzi F; Salati E; Roman JJ; Lim S; Hermonat PL
Cancer Gene Ther; 2001 Dec; 8(12):948-57. PubMed ID: 11781657
[TBL] [Abstract][Full Text] [Related]
23. Recombinant adenovirus expressing GP5 and M fusion proteins of porcine reproductive and respiratory syndrome virus induce both humoral and cell-mediated immune responses in mice.
Jiang W; Jiang P; Li Y; Tang J; Wang X; Ma S
Vet Immunol Immunopathol; 2006 Sep; 113(1-2):169-80. PubMed ID: 16777236
[TBL] [Abstract][Full Text] [Related]
24. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
[TBL] [Abstract][Full Text] [Related]
25. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
26. Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses.
Sharpe S; Fooks A; Lee J; Hayes K; Clegg C; Cranage M
Virology; 2002 Feb; 293(2):210-6. PubMed ID: 11886240
[TBL] [Abstract][Full Text] [Related]
27. Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system.
Walczak M; Regts J; van Oosterhout AJ; Boon L; Wilschut J; Nijman HW; Daemen T
Antivir Ther; 2011; 16(2):207-18. PubMed ID: 21447870
[TBL] [Abstract][Full Text] [Related]
28. [Preventive and therapeutic effect of genetic vaccine based on recombinant alpha virus against mouse mastocytoma P815].
Ni B; Yang RG; Li YQ; Wu YZ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Jan; 20(1):45-8. PubMed ID: 15182620
[TBL] [Abstract][Full Text] [Related]
29. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene.
Colmenero P; Liljeström P; Jondal M
Gene Ther; 1999 Oct; 6(10):1728-33. PubMed ID: 10516722
[TBL] [Abstract][Full Text] [Related]
30. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses.
Yan Q; Cheung YK; Cheng SC; Wang XH; Shi M; Hu MH; Yong X
Gynecol Oncol; 2007 Jan; 104(1):199-206. PubMed ID: 17049969
[TBL] [Abstract][Full Text] [Related]
31. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA.
Velders MP; McElhiney S; Cassetti MC; Eiben GL; Higgins T; Kovacs GR; Elmishad AG; Kast WM; Smith LR
Cancer Res; 2001 Nov; 61(21):7861-7. PubMed ID: 11691804
[TBL] [Abstract][Full Text] [Related]
32. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector.
Guan M; Rodriguez-Madoz JR; Alzuguren P; Gomar C; Kramer MG; Kochanek S; Prieto J; Smerdou C; Qian C
Cancer Res; 2006 Feb; 66(3):1620-9. PubMed ID: 16452221
[TBL] [Abstract][Full Text] [Related]
33. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
34. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.
Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH
J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071
[TBL] [Abstract][Full Text] [Related]
35. Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors.
Kunke D; Grimm D; Denger S; Kreuzer J; Delius H; Komitowski D; Kleinschmidt JA
Cancer Gene Ther; 2000 May; 7(5):766-77. PubMed ID: 10830724
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
37. Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition.
Samorski R; Gissmann L; Osen W
Immunol Lett; 2006 Sep; 107(1):41-9. PubMed ID: 16949679
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response.
Tan J; Yang NS; Turner JG; Niu GL; Maassab HF; Sun J; Herlocher ML; Chang AE; Yu H
Cancer Gene Ther; 1999; 6(4):331-9. PubMed ID: 10419051
[TBL] [Abstract][Full Text] [Related]
39. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT
Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088
[TBL] [Abstract][Full Text] [Related]
40. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.
Préville X; Ladant D; Timmerman B; Leclerc C
Cancer Res; 2005 Jan; 65(2):641-9. PubMed ID: 15695409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
